Hot topics
Making premature CHD history
Dr Samuel Gidding discusses how treating children with FH early can make premature CHD history
read more »How to identify children with FH
Dr Samuel Gidding discusses how to identify children with FH
read more »Safety of lowering LDL-C
Dr Albert Wiegman discusses the safety of lowering LDL C in FH children
read more »EAS Consensus Panel on Paediatric FH
Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Spanish Dr Raul Santos discusses the EAS Consensus Panel statement on FH in children – Portuguese
read more »Statin Associated Muscle Symptoms – a role for PCSK9 inhibitors? Professor Erik Stroes, Academic Medical Center, Amsterdam, the Netherlands comments
The latest European Atherosclerosis Society Consensus Panel focused on statin associated muscle symptoms (SAMS),1 which at present accounts for up to 40% of referrals to specialised lipid clinics. The veracity of SAMS has been questioned given the apparent discrepancy between findings from clinical trials and…
read more »Statins and muscle symptoms: New EAS Consensus Panel statement
The European Atherosclerosis Society (EAS) Consensus Panel has published new guidance on the diagnosis, assessment and treatment of statin-associated muscle symptoms (SAMS). Unique to this statement is an overview of current understanding of the pathophysiology of statin myopathy. Without doubt, statins are the therapeutic cornerstone…
read more »Lifetime exposure and primordial prevention
Atherosclerosis is a slow onset insidious disease. It is asymptomatic until its manifestations cause significant morbidity and mortality. There is no cheap easy way to detect it. As a result disease management strategies rely on epidemiologically-based risk calculators to identify individuals likely to have significant…
read more »IMPROVE-IT: Trial data follow through on genetics
An ATVB editorial implies that results from IMPROVE-IT could have been predicted by considering genetics data. In a previous report from the Myocardial Infarction Genetics Consortium Investigators,1 carriage of inactivating mutations that attenuate Niemann-Pick C1-like 1 (NPC1L1) function reduced both LDL cholesterol and also protected…
read more »Enhancing and Improving cardiovascular outcomes
Implications from IMPROVE-IT: Perspective from Anthony S. Wierzbicki* The link between low density lipoprotein-cholesterol (LDL-C) and cardiovascular disease (CVD) is well established 1 2 . Statins are the first-line drug therapy for the treatment of lipid-associated CVD risk. However the role of second line therapies…
read more »Latest IMPROVE-IT commentary
read more »LDL-C: how low should clinicians aim for?
Trials with monoclonal antibodies – PCSK9 inhibitors – will answer the question of how far should low density lipoprotein cholesterol (LDL-C) be reduced?
read more »Lowering LDL-C: How low and for how long?
Treatment to reduce low density lipoprotein cholesterol (LDL-C) should be started in teenage years in people with very high risk of cardiovascular death or events e.g. heart attacks. There is substantial evidence showing significant benefits if LDL-C is reduced by about 50%, Professor Evan Stein…
read more »IMPROVE-IT: will it prove anything?
Professor Anthony S. Wierzbicki, London UK Comments on the IMPROVE-IT debate Cardiovascular disease (CVD) guidelines are emphasising the use of clinical outcome data on major vascular events (American Heart Association/American College of Cardiology)1 or hard CVD events alone (UK NICE)2 . They have begun to…
read more »Lowering LDL-C : at what level would this impact the benefit vs. risk ratio?
Emeritus Research Professor, Institut de recherches cliniques de Montréal (IRCM), Canada Potent inhibitors of pro-protein convertase-subtilisin-kexin-9 (PCSK9) have the capacity to reduce plasma low-density lipoprotein cholesterol (LDL-C) to unprecedentedly low levels, especially if combined with statins. This discovery raises several important questions; how low should…
read more »